Table 4.

List of recent findings on in situ CAR cell therapy. Updated till 07/04/2024.

Reference	State	Target Antigen	Vehicle	Target Cell
Magee et al. [62].	Preclinical	–	Lipid nanoparticle	T cell
Parker et al. [108].	Preclinical	CD20	Lentiviral vector	T cell
Mei et al. [109].	Preclinical	CD3	Lentiviral vector	T cell
Krotova et al. [110].	Preclinical	CD19	Lentiviral vector	T cell
Andorko et al. [111].	Preclinical	CD20	Lentiviral vector	T cell and NK cell
Beltran-Garcia et al. [112].	Preclinical	–	Lipid nanoparticles and virus-like particles	T cell, NK cell and macrophage
Green et al. [113].	Preclinical	CD19	Fusosomes (viral vectors pseudotyped with modified paramyxovirus envelopes targeting specific cell types)	T cell
Rurik et al. [114].	Preclinical	CD5	Lipid nanoparticle	T cell
Smith et al. [115].	Preclinical	CD3	PBAE polymers with PGA coating	T cell
Parayath et al. [116].	Preclinical	CD8	PBAE polymers with PGA coating	T cell